Stock Watch

Leading pharmaceutical firm Aurobindo Pharma has declared its year-end financial results for the fiscal year 2009-10 and it has posted a remarkable rise in net profit figure. It is almost five fold in this fiscal year.

The company has registered a net profit of Rs 563.4 crore for the year that ended in 31st March, 2010.

The net profit was reported to be Rs 100.26 crore for the financial year 2008-09. This net profit figure has grown up by over five times in this year as compared to the last fiscal. This has been informed by the firm in a filing at the Bombay Stock Exchange.

Aurobindo Pharma, one of the largest API manufacturers in Asia, has secured final nod from US Food and Drug administration (USFDA) for two ANDAs namely Cefotaxime for injection USP in the strength of 500 mg, 1g, 2g and Cefotaxime for injection USP 10g in pharmacy bulk pack.

Aurobindo Pharma, a leading Hyderabad based drug firm, has secured nod from the South African regulator to manufacture and market two drugs in that country.

The company received the permission from South African (SA) Medicines Control Council (MCC) for Auro Ampicillin injection in the strength of 500 mg and 1,000 mg and Auropidone tablets, in 0.5 mg strength.

Hyderabad-based Aurobindo Pharma has finally secured the final approval from the US Food and Drug Administration (USFDA) for Fluconazole in the strength of
50mg/5ml, 200mg/5ml.

Fluconazole is a triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infections.

The shares of Aurobindo Pharma today settled at Rs 690 on BSE, up 2 percent compared to its previous close. The counter has 52-week-high and low of Rs 725 and Rs
102 respectively.

Aurobindo Pharma, a leading drug manufacturing company, has acquired all stake in Trident Life Sciences, a clinical research organisation (CRO), for an estimated Rs 134 crore in a bid to make its entry in injectable domain.

The move will help the firm to scale new heights in the pharmaceutical sector by providing enhanced manufacturing, distribution, services and solutions to its clients.

Aurobindo Pharma, one of the largest API manufacturers in Asia, has finally agreed to acquire Hyderabad-based Trident Life Sciences (TLSL) for an undisclosed amount.

The company stated in a release that the board has approved the acquisition of 100% stake of TLSL. However, the deal is subject to suitable agreements between the parties for the same and conditions customary to the closing of the transaction.

Aurobindo Pharma, one of the largest API manufacturers in Asia, has informed that it has received the final approval for Carisoprodol tablets USP 350mg from the US Food & Drug Administration (USFDA).

Hyderabad-based Aurobindo Pharma has informed that it has received the tentative approval for Donepezil Hydrochloride Tablets 5mg and 10mg from the US Food and Drug Administration (USFDA).

Donepezil Hydrocholoride Tablet 5mg and 10 mg is the generic equivalent to Aricept Tablets 5mg and 10mg of Eisai Medical Research Inc.

Aurobindo Pharma Limited, one of the largest API manufacturers in Asia, has notified that its US-based joint venture firm has secured approval from the drug regulator for its anti-bacterial veterinary drug.

Pfizer, the world's largest research-based pharmaceutical company, has entered into an agreement with the Hyderabad-based Aurobindo Pharma to sell generic medicines in the US and Europe.

The latest deal with the Hyderabad-based firm is an extension of the agreement which the companies had signed in July last year, for about five products.